Eleven Biotherapeutics (EBIO) & Lipocine (LPCN) Head-To-Head Survey

Eleven Biotherapeutics (NASDAQ: EBIO) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility and Risk

Eleven Biotherapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Eleven Biotherapeutics and Lipocine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eleven Biotherapeutics 0 0 0 0 N/A
Lipocine 0 1 3 0 2.75

Lipocine has a consensus price target of $13.50, indicating a potential upside of 892.65%. Given Lipocine’s higher probable upside, analysts clearly believe Lipocine is more favorable than Eleven Biotherapeutics.

Institutional and Insider Ownership

3.8% of Eleven Biotherapeutics shares are owned by institutional investors. Comparatively, 22.1% of Lipocine shares are owned by institutional investors. 21.0% of Eleven Biotherapeutics shares are owned by company insiders. Comparatively, 11.3% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Eleven Biotherapeutics and Lipocine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eleven Biotherapeutics N/A -94.68% -29.28%
Lipocine N/A -74.63% -68.41%

Valuation & Earnings

This table compares Eleven Biotherapeutics and Lipocine’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eleven Biotherapeutics $29.98 million 0.87 $1.89 million ($1.07) -0.77
Lipocine N/A N/A -$18.97 million ($0.96) -1.42

Eleven Biotherapeutics has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Eleven Biotherapeutics, indicating that it is currently the more affordable of the two stocks.


Eleven Biotherapeutics beats Lipocine on 6 of the 11 factors compared between the two stocks.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Lipocine Company Profile

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply